Compare Ascendis Pharma A/S (ASND) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while iShares 3 7 Year Treasury Bond ETF trades at $116.77. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | IEI | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Fixed Income |
52-Week High | $277.18 | $120.72 |
52-Week Low | $163.32 | $116.67 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
IEI (iShares 3-7 Year Treasury Bond ETF) trades at $116.77, down slightly by 0.06% amid broader market volatility. The technical picture remains bearish with moving averages signaling continued pressure, though oscillators show neutral momentum. Recent dividend payments of $0.36-$0.37 highlight the fund's income generation, while bond market uncertainty persists with mixed signals on Federal Reserve policy direction.
The outlook for IEI remains cautious as Treasury yields face upward pressure from inflation concerns and potential Fed rate hikes. While the ETF offers lower volatility than corporate bonds, competition from higher-yielding alternatives like Vanguard's bond ETFs presents headwinds. Key risks include interest rate sensitivity and shifting investor preferences toward higher-yield fixed income options.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
